Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

354

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Schizophrenia
Interventions
DRUG

RBP-7000

RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.

DRUG

Placebo

Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.

DRUG

Risperidone

Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).

Trial Locations (32)

11516

Neurobehavioral Research, Inc., Cedarhurst

19139

CRI Lifetree, Philadelphia

28204

New Hope Clinical Research, Charlotte

32751

Florida Clinical Research Center, LLC, Orlando

33021

Behavioral Clinical Research, Inc., North Miami

33308

Innovative Clinical Research, Fort Lauderdale

45417

Midwest Clinical Research Center, LLC, Dayton

60169

Alexian Brothers Behavioral Health Hospital, Hoffman Estates

60640

Uptown Research Institute, Chicago

63118

St. Louis Clinical Trials, St Louis

63128

PsychCare Consultants Research, St Louis

67214

Via Christi Research, Wichita

70629

Lake Charles Clinical Trials, LLC, Lake Charles

72211

Woodland International Research Group, Inc., Little Rock

72764

Woodland International Research Group, Inc., Springdale

73112

Oklahoma Clinical Research Center, Oklahoma City

75231

FutureSearch Clinical Trials, L.P., Dallas

75243

Pillar Clinic Research, LLC, Dallas

78734

FutureSearch Clinical Trials, L.P., Austin

78754

Community Clinical Research, Inc., Austin

89102

Altea Research Institute, Las Vegas

90660

CNRI- Los Angeles, LLC, Pico Rivera

90703

Comprehensive Clinical Development - Cerritos, CA, Cerritos

90806

Collaborative Neuroscience Networks, Inc., Long Beach

90813

Apostle Clinical Trials, Inc., Long Beach

91206

Behavioral Research Specialists, LLC, Glendale

92012

CNRI - San Diego, LLC, San Diego

92025

Synergy Clinical Research of Escondido, Escondido

92056

Excell Research, Inc., Oceanside

94612

Pacific Research Partners, Oakland

71104-2136

J. Gary Booker, MD, APMC, Shreveport

08053

CRI Lifetree, Marlton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT02109562 - Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients | Biotech Hunter | Biotech Hunter